晶華微(688130.SH):會持續加大優秀研發人才引進
格隆匯6月2日丨有投資者向晶華微(688130.SH)提問:公司研發費用大幅增長的原因是什麼?
晶華微回覆:公司2022年研發費用4,785.98萬元,同比增長52.78%,研發投入佔營業收入的比例為43.10%,同比增加25.04個百分點;2023年一季度研發費用1,544.22萬元,同比增長99.35%;主要系公司加大研發投入,研發人員支出及材料投入增加所致。公司重視研發投入,會持續加大優秀研發人才引進,繼續圍繞醫療健康、工控儀表、智能感知等相關領域及電池管理、模擬信號鏈等相關產品開展研發設計,深化產學研合作創新,促進技術成果轉化,加快新產品推出和產品佈局,推進研發進度,以便產品能更快投入市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.